120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
研究进展对应用和机制的百合地黄汤在重度抑郁障碍
Authors Yang L, Wang Y, Wan H , Feng H, Liu Y, Xue G, Zhi Y, Zhang F, Liu Y, Zhang Z
Received 6 November 2025
Accepted for publication 17 December 2025
Published 4 February 2026 Volume 2026:20 579207
DOI https://doi.org/10.2147/DDDT.S579207
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Anastasios Lymperopoulos
Longlong Yang,1,* Yilong Wang,1,* Hejia Wan,1,* Hao Feng,1,* Yi Liu,1 Guimin Xue,1 Yanle Zhi,1 Fengjiao Zhang,2 Yongsheng Liu,3 Zhiqiang Zhang1
1School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China; 2School of Food Science, Henan University of Animal Husbandry and Economy, Zhengzhou, Henan, People’s Republic of China; 3Medical Examination Center, Henan Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou, Henan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiqiang Zhang, School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China, Email zhiqiangzhang2022@163.com
Objective: The treatment of major depressive disorder (MDD) is often plagued by inadequate therapeutic efficacy, high relapse rates, and adverse drug effects. Baihe Dihuang Decoction (BHDH, Lily Bulb and Rehmannia Decoction), a classic Traditional Chinese Medicine (TCM) formula, shows promise for depression, but a comprehensive synthesis of modern evidence is warranted. This study aimed to review the clinical efficacy, pharmacological mechanisms, and safety profile of BDD for MDD to inform its clinical application and guide future research.
Methods: A systematic literature search was conducted in both English (PubMed, Web of Science) and Chinese (CNKI, Wanfang) databases from inception to June 2025. For clinical evidence, the search focused on “Baihe Dihuang Decoction”, “major depressive disorder/depression”, and “randomized controlled trial”. Supplementary searches using terms like “chemical constituents” and “pharmacological action” were performed for mechanistic studies. Relevant literature was subsequently summarized and analyzed.
Results: Current evidence suggests that BHDH, as an adjunct to conventional antidepressants, can improve the overall clinical response rate, reduce Hamilton Depression Rating Scale scores, and potentially alleviate adverse reactions. Its active constituents may exert antidepressant effects via multiple pathways, including monoaminergic neurotransmission modulation, neuroinflammation inhibition, hypothalamic-pituitary-adrenal axis regulation, hippocampal neuron protection, and gut microbiota modulation. However, its efficacy as a monotherapy and long-term safety profile require further validation through high-quality clinical trials.
Conclusion: BHDH possesses a multi-target pharmacological basis for antidepressant activity. Existing clinical evidence supports its effectiveness and relative safety as an adjunctive therapy for MDD. To better define its clinical role and advance TCM modernization, future research should prioritize rigorous randomized controlled trials, elucidate its formula compatibility mechanisms, and identify its key bioactive components.
Keywords: Baihe Dihuang decoction, history of development, chemical composition, major depressive disorder, mechanism of action
1School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China; 2School of Food Science, Henan University of Animal Husbandry and Economy, Zhengzhou, Henan, People’s Republic of China; 3Medical Examination Center, Henan Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou, Henan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiqiang Zhang, School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China, Email zhiqiangzhang2022@163.com
Objective: The treatment of major depressive disorder (MDD) is often plagued by inadequate therapeutic efficacy, high relapse rates, and adverse drug effects. Baihe Dihuang Decoction (BHDH, Lily Bulb and Rehmannia Decoction), a classic Traditional Chinese Medicine (TCM) formula, shows promise for depression, but a comprehensive synthesis of modern evidence is warranted. This study aimed to review the clinical efficacy, pharmacological mechanisms, and safety profile of BDD for MDD to inform its clinical application and guide future research.
Methods: A systematic literature search was conducted in both English (PubMed, Web of Science) and Chinese (CNKI, Wanfang) databases from inception to June 2025. For clinical evidence, the search focused on “Baihe Dihuang Decoction”, “major depressive disorder/depression”, and “randomized controlled trial”. Supplementary searches using terms like “chemical constituents” and “pharmacological action” were performed for mechanistic studies. Relevant literature was subsequently summarized and analyzed.
Results: Current evidence suggests that BHDH, as an adjunct to conventional antidepressants, can improve the overall clinical response rate, reduce Hamilton Depression Rating Scale scores, and potentially alleviate adverse reactions. Its active constituents may exert antidepressant effects via multiple pathways, including monoaminergic neurotransmission modulation, neuroinflammation inhibition, hypothalamic-pituitary-adrenal axis regulation, hippocampal neuron protection, and gut microbiota modulation. However, its efficacy as a monotherapy and long-term safety profile require further validation through high-quality clinical trials.
Conclusion: BHDH possesses a multi-target pharmacological basis for antidepressant activity. Existing clinical evidence supports its effectiveness and relative safety as an adjunctive therapy for MDD. To better define its clinical role and advance TCM modernization, future research should prioritize rigorous randomized controlled trials, elucidate its formula compatibility mechanisms, and identify its key bioactive components.
Keywords: Baihe Dihuang decoction, history of development, chemical composition, major depressive disorder, mechanism of action